Menu
Recruiting NCT04695782

Pencil Beam Proton Therapy for Pelvic Recurrences in Rectal Cancer Patients Previously Treated With Radiotherapy

Phase II Interventional Rectal Cancer Recurrent

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Pencil beam proton radiotherapy.
Who it may be relevant to
Registry conditions: Rectal Cancer Recurrent. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Denmark
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

Study design: A prospective phase II, non-randomized observational study of dose-escalated pencil beam proton therapy re-irradiation for pelvic recurrences from rectal cancer. Re-irradiation is either a part of neo-adjuvant treatment or as a definitive treatment strategy for un-resectable recurrences.

Interventions

  • Radiation Pencil beam proton radiotherapy
    Doseescalated pencil beam proton Therapy

Primary outcome measures

  • R0-resection [Time frame: 5-6 years]
  • 1-year local control [Time frame: 6-7 years]
Secondary outcome measures (5)
  • Local recurrence [Time frame: 6-8 years]
  • Disease free survival [Time frame: 10 years]
  • Overall survival [Time frame: 10 years]
  • Toxicity [Time frame: 5-7 years]
  • Patient reported outcomes [Time frame: 5-7 year]

Eligibility criteria

Inclusion criteria

  • • Locally recurrent rectal cancer.
  • Bioptically verified (adenocarcinoma )
  • Available dose plan from primary radiotherapy
  • Previous pelvic RT (>30Gy EQD2)
  • Evaluated in MDT-conferences (Herlev, Aarhus)
  • Age>18 years
  • PS 0-2
  • Adequate organ function
  • Informed consent

Exclusion criteria

  • Non-resectable distant metastases (PET-CT)
  • Unable to undergo MRI, PET-CT
  • Inability to attend full course radiotherapy and follow up in the out patient clinic.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Non-randomized
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

Denmark · 1 center
  • Danish Centre for Particle Therapy — Aarhus

Identifiers

NCT: NCT04695782 · DCPT221020

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗